Summary of H2020-ERC-2016-CONSOLIDATOR GRANT 725091-MITOMAD.
Functional characterisation of mitochondrial metabolic adaptations to innate sensing in dendritic cell subsets.
The general issue being addressed by our project is how dendritic cells (DCs) and macrophages sense the tissue environment and microbial, how they translate this sensing into metabolic signals, with a particular focus on mitochondrial metabolism, and how this knowledge can be applied for improved immunotherapy. This project aim to identify new targets to exploit DCs for improved immunotherapy and this may generate new therapeutic strategies in diseases related to the immune system, ranging from tackling antibiotic-resistance by learning about the metabolic requirements of trained immunity, modulating responses to dampen immunity in autoimmunity, chronic inflammation or asthma, or enhancing immunity against tumors. The overall objectives are:
- Characterize the metabolic reprogramming after DC stimulation, with particular emphasis in analysis of mitochondrial metabolism.
- Dissection of molecular mechanisms connecting innate sensing and mitochondrial adaptations in DCs.
- Analysis of the impact of manipulation of mitochondrial biology on DC metabolism and function.
- Assess the functional in vivo effects of targeting mitochondrial biology in DCs in homeostasis and disease.
Molecular Regulation of macrophage and dendritic cell function.
Ref: PID2019-108157RB
Participant Institution: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI: David Sancho Madrid.
Funding Institution: Ministerio de Ciencia e Innovación. Agencia Estatal de Investigación.
From: 01/06/2020
To: 31/05/2023
Total Amount: 435,600€ + 1 pre-doctoral fellowship.
Inmunidad Tumoral e Inmunoterapia del Cáncer (IMMUNOTHERCAN-CM)
Ref: B2017/BMD-3733.
Participant Institution: Consortium with node in the Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI of the IMMUNOBIOL group at CNIC: David Sancho Madrid.
Funding Institution: Ayudas para la realización de Programas de Actividades de I+D entre Grupos de Investigacion de la Comunidad de Madrid en Tecnologías y en Biomedicina, cofinanciado con Fondos Estructurales. Comunidad de Madrid.
From: 01/01/2018
To: 31/12/2021
Total Amount for consortium (9 groups): 952.472,28€
Brain-gut cross-talk in stroke: targeting gut barrier dysfunction and immune responses to improve stroke outcome
Exp: 130/C/2017.
Participant Institution: Collaborative project with the Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI CNIC node: David Sancho Madrid.
Funding Institution: Ayudas a la investigación en ictus y lesiones medulares y cerebrales traumáticas. Fundación La Marató de TV3.
From: 2018 (duration 3 years).
Total Amount for CNIC node: 86.250€
Red de Esclerosis multiple
Programa: Patogenia MS: neuroinflammacion y neuodegeneracion
Exp: RD16/0015/0018.
Participant Institution: Network with node in the Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI: David Sancho Madrid.
Funding Institution: Redes Temáticas de Investigación Cooperativa (RETICS) 2016 Instituto de Salud Carlos III.
From: 01/01/2017
To: 31/12/2021
Total Amount for CNIC node: 11.000 €
Functional characterisation of mitochondrial metabolic adaptations to innate sensing in dendritic cell subsets.
H2020-ERC-2016-CONSOLIDATOR GRANT 725091-MITOMAD.
Participant Institution: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI: David Sancho Madrid.
Funding Institution: European Commission, H2020.
From: 01/12/2017
To: 30/11/2022
Total Amount: 1,995,000€
Caracterización Funcional de la Regulación de la Inmunidad Innata y Adaptativa por las Células Dendríticas.
Participant Institution: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI: David Sancho Madrid.
Funding Institution: Ministerio de Economía, Industria y Competitividad. SAF2016-79040-R.
From: 01/12/2016
To: 30/11/2019
Total Amount: 290,000€
PROCROP-Professional cross-priming for ovary and prostate cancer.
Participant Institution: Consortium with node in the Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI CNIC node: David Sancho Madrid.
Funding Institution: EU Framework Programme for Research and Innovation H2020. Call: H2020-PERSONALISING HEALTH AND CARE (H2020-PHC-2014-two-stage).
From: 01/09/2015
To: 31/08/2020
Total amount for CNIC node: 655,000€
Immunotherapy by targeting dendritic cells with nanoparticles.
Participant Institution: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III.
PI: David Sancho Madrid.
Funding Institution: Fondation Acteria.
From: 2017
To: 2019
Total amount: 150,000€
Boosting anti-tumour immunity by targeting dendritic cell-T cell interactions with bispecific antibodies. (WWCR 25-0080)
PI: David Sancho Madrid.
Funding Institution: Worldwide Cancer Research.
From: 2025
To: 2027
Total amount: 206,040 GBP
Generation of bispecific antibodies targeting T lymphocytes and dendritic cells to increase their interaction in the tumor setting and promote anti-tumor immunity. (PRYGN246642SANC)
PI: David Sancho Madrid.
Funding Institution: Proyectos Generales AECC 2024.
From: 2024
To: 2026
Total amount: 295,000 €
Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis (ImnovAth)
PI: David Sancho Madrid.
Funding Institution: European Union ERC-2023-PoC-GA-101158245.
From: 01/09/2024
To: 28/02/2026
Total amount: 150,000 €
Targeting Imidazole propionate in atherosclerosis
Institutions: CNIC and Kaertor Foundation
PI and Coordinator (CNIC): David Sancho Madrid.
Funding Institution: La Caixa Foundation (LCF/PR/HR23/52430012)
From: 01/12/2023
To: 30/11/2026
Total amount: 967,620.20 € (717,000 € for CNIC node)
Connecting myeloid cell metabolism and function (MYMETFUN)
PI: David Sancho Madrid.
Funding Institution: Ministerio de Ciencia e Innovación. Agencia Estatal de Investigación
Project ID: PID2022-137712OB-I00
From: 01/09/2023
To: 31/08/2026
Amount granted: 575,000 € + 1 FPI fellowship
Conditional costimulation through 4-1BB that exploits cross-priming in cancer (CONDICOS)
Funding Institution: Ministerio de Ciencia e Innovación. Agencia Estatal de Investigación
Project ID: CPP2022-009762 (Colaboración público-privada 2022)
From: 01/11/2023
To: 31/10/2026
Participants and Funding:
LEADARTIS SL (PI: Juan José Pérez-Villar): 523,638.03 €
CNIC (PI: D. Sancho): 176,700.40 €
Universidad de Navarra (PI: Ignacio Melero): 184,763 €
CNIO (PI: Luis Álvarez-Vallina): 184,731 €
Immunomodulatory strategies in vascular remodeling: new diagnostic and therapeutic perspectives (INMUNOVAR-CM)
Participant Institutions: CNIC, FJD, UCM
Consortium Coordinator: Almudena Ramiro
PI (CNIC): D. Sancho
Funding Institution: Comunidad de Madrid – Programas de Actividades de I+D entre Grupos de Investigación (Biomedicina 2022)
From: 01/01/2023
To: 31/12/2026
Total amount (consortium): 824,000 € (5 groups)
Total amount (DS group): approx. 200,000 €
The crosstalk of microbiota and trained immunity for the development of trained immunity-based immunotherapies
Participant Institutions: Inmunotek S.L (Coordinator), CNIC (Partner)
PI (CNIC): David Sancho Madrid.
Funding Institution: Ministerio de Ciencia e Innovación. Agencia Estatal de Investigación
Project ID: CPP2021-008310
From: 01/11/2022
To: 31/10/2025
Total amount (consortium): 723,616 €
Total amount (DS group): 328,315 €
